Navigation Links
Tests between colonoscopies could be lifesaver for high-risk patients
Date:12/7/2010

Among patients with a family or past history of colorectal cancer (CRC), testing between colonoscopies helps detect CRC and advanced tumors that are either missed or develop rapidly, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

"By using fecal immunochemical testing a new type of stool blood test in the interval between surveillance colonoscopies, we were able to detect cancer much sooner than if we had waited for the scheduled surveillance," said Graeme P. Young, MD, AGAF, FRACP, of Flinders Medical Centre, Australia and lead author of the study. "In fact, in those patients who consistently returned a negative fecal immunochemical test, the chance of finding cancer or advanced adenoma was significantly reduced."

A joint guideline from the American Cancer Society, the U.S. Multi-Society Task Force on Colorectal Cancer and the American College of Radiology recommends that average-risk adults, beginning at the age of 50, should receive a colonoscopy every ten years and that annual fecal immunochemical tests (FIT) are acceptable choices for CRC screening in between this ten-year span (any positive FIT should be followed up with a colonoscopy).1 Guidelines suggest more frequent colonoscopies for certain high-risk groups.

In this study, 1,736 patients with a confirmed family or personal history of CRC were followed for 8,863 person years of surveillance; some for as long as 20 years. The study inclusion criteria required that patients had received at least an initial and one subsequent surveillance colonoscopy with adequate examination and retrieval of tissue, performed with a training-accredited colonoscopist present. In the 1,071 asymptomatic subjects who returned at least one FIT after the colonoscopies, the test detected 12 out of 14 cancers and 60 out of 96 advanced adenomas. In FIT-positive cases, the diagnosis was made sooner by 25 months for cancer and by 24 months for advanced adenomas before the regularly scheduled colonoscopy.

"Our study results suggest that interval fecal immunochemical testing in a high-risk colonoscopy program can be used for detecting missed or rapidly developing lesions," added Dr. Young.

Patients at increased risk for developing CRC due to a family history or past history of CRC are recommended to have colonoscopic surveillance at regular intervals, often more frequently than recommended for the average-risk population. Patients with only one or two small adenomas with low-grade dysplasia are recommended to have their second surveillance colonoscopy after an interval of 10 years. However, for these individuals, there is a greater risk of delay in detecting rapidly progressing or missed lesions. Using annual fecal occult blood tests in the interval between surveillance colonoscopies could be a strategy that helps manage this risk. FIT, which uses an antibody specific for human hemoglobin, is being increasingly used because it is more sensitive for cancer and adenomas.


'/>"/>

Contact: Alissa J. Cruz
media@gastro.org
301-272-1603
American Gastroenterological Association
Source:Eurekalert

Related medicine news :

1. International clinical trial tests targeted drug for melanoma
2. Common for patients to undergo multiple cardiac imaging tests, with high cumulative radiation dose
3. Study raises concern about ability of tests to predict fertility
4. Fatalistic Attitudes May Keep Hispanic Women From Cancer Tests
5. Newborn Hearing Tests More Effective Than Later Screening
6. Experts say direct-to-consumer genetic tests need innovative oversight
7. Friends, family detect early Alzheimers signs better than traditional tests
8. Sam's Club Tests Online Small Business Loan Program for Main Street
9. Fresh findings about chickenpox could lead to better blood tests
10. ASCO data show serum DNA blood tests detect cancers with high sensitivity and specificity
11. Fox Chase clinical trial tests first of its kind antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... June 27, 2017 , ... Hammer Strength, the world’s leading performance strength training ... of the Houston Rockets the NBSCA Strength & Conditioning Coach of the Year. ... members who vote to select the coach who embodies the highest level of excellence ...
(Date:6/27/2017)... ... 27, 2017 , ... A+ Orthodontics is now offering special ... on treating alignment and occlusion irregularities. Treatment often includes the use of braces ... Hollywood dentist , Dr. Garemani, along with Dr. Reza and the rest of ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... Children’s National ... Children’s Hospitals rankings, with its Neonatology program ranking #1 out of more than ... also named to the coveted Honor Roll, a distinction given to the top performing ...
(Date:6/26/2017)... ... ... Antoine Dental Center is now offering various types of dental implants to restore ... support for prosthetic teeth, such as crowns, bridges, or dentures. An implant is placed directly ... new root for the tooth. , Several types of dental implants are available, including: ...
(Date:6/26/2017)... ... June 26, 2017 , ... The Centers for Advanced Orthopaedics ... of Richard Robinson as chief operating officer (COO). In this role, Robinson brings ... track record of simplifying business processes and developing growth strategies to increase market ...
Breaking Medicine News(10 mins):
(Date:6/16/2017)... , June 16, 2017  Exactly 50 years ago ... off what later became known as the San Francisco "Summer ... ) is unveiling two radical innovations in strategic market research ... This announcement marks the beginning of Northern Light,s "Summer of ... ...
(Date:6/14/2017)... , June 14, 2017  In 2016, ... Creative Startups pitch competition and came away with ... platform is described by Forbes as "entering the life ... Medical Association as teaching "empathy to medical professionals in ... startup was recently named a finalist for the Department ...
(Date:6/11/2017)... and Company (NYSE: LLY ) announced today ... an investigational treatment for the prevention of episodic and ... endpoints for galcanezumab compared to placebo at both studied ... REGAIN) will be presented today at the American Headache ... . "The detailed Phase 3 ...
Breaking Medicine Technology: